SCHEMBL12431050

SCHEMBL12431050

CC(=O)Nc1ccc(Oc2cc(Nc3cc(C)[nH]n3)ccn2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 7/20 0.55
▸ AURKB Q96GD4 5/20 0.55
▸ KMT2A Q03164 1/20 0.51
▸ EGFR P00533 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ POLB P06746 1/20 0.44
▸ SRC P12931 1/20 0.44
▸ GSK3B P49841 1/20 0.44
▸ AURKC Q9UQB9 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ MPI P34949 1/20 0.44
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ SYK P43405 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ BRAF P15056 1/20 0.43
▸ TNIK Q9UKE5 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12430993 0.78 AURKB (0.69) AURKAAURKBSRCGSK3BAURKC
SCHEMBL13054789 0.77 AURKA (0.39) AURKAAURKBKMT2AEGFRALDH1A1
SCHEMBL12431032 0.76 AURKA (0.58) AURKAAURKBKMT2ASMN1; SMN2POLB
SCHEMBL3961728 0.73 AURKA (0.52) AURKAAURKBEGFRALDH1A1SMN1; SMN2
SCHEMBL3967694 0.72 AURKA (0.51) AURKAAURKBEGFRALDH1A1SMN1; SMN2
SCHEMBL12430887 0.72 AURKA (0.68) AURKAAURKBKMT2AEGFRALDH1A1
SCHEMBL3965081 0.72 AURKA (0.51) AURKAAURKBEGFRALDH1A1SMN1; SMN2
SCHEMBL12430843 0.71 AURKB (1.00) AURKAAURKBSRCGSK3BAURKC
SCHEMBL12430905 0.71 AURKB (0.57) AURKAAURKBEGFRALDH1A1SMN1; SMN2
SCHEMBL3966678 0.71 AURKA (0.50) AURKAAURKBEGFRALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 — — US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 — — US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 — — US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, AURKC, AURKA AURKA 3/4885AURKB 7/4885KMT2A 850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback